Close Menu

At the Bio-IT conference this week, Microsoft introduced Amalga Life Sciences, according to Bio-IT World. Amalga is part of Microsoft's "plan create a single information highway and data aggregation/modeling platform that spans basic research, clinical trials, health care delivery, and consumer health information needs." With this Microsoft will be targeting academic medical centers, biotechs, and pharma. Consider yourself warned.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novamax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.